If European League Against Rheumatism guidelines are followed, when a patient with rheumatoid arthritis (RA) does not reach remission or a state of low disease activity after 6 months of treatment, then the patient’s treatment should be modified regardless of the drug therapy being used (biologic or small molecule).
Approximately 1% of the global population has rheumatoid arthritis (RA), and treating RA is costly, especially when biologic drugs are necessary after the failure of small-molecule drugs. A recent study conducted in Poland sought to understand how patients diagnosed with RA progressed through treatments for their disease.
Using the Polish National Health Fund data, researchers identified 1167 patients with RA who began therapy in 2009. The patients, who were followed until 2014, initiated treatment with the following drugs financed under the government’s public payer program: the small-molecule leflunomide (53.6%) and the biologics adalimumab (5.8%), etanercept (14.4%), infliximab (23.1%), and rituximab (3%).
During the first year of treatment, 80.9% of patients continued to receive adalimumab, 85.4% continued to receive etanercept, 84.1% continued to receive infliximab, and 74.9% continued to receive leflunomide. In total, 186 patients (16%) stopped or paused therapy after the first year, and during the 2 following years, 754 patients (65%) did so.
The most therapy changes occurred for patients who had started treatment with infliximab; after year 6, 96% of patients had changed from infliximab to another option. Adalimumab had the second highest frequency of changes, with 85% of patients changing drugs by year 6.
The authors of the study say that, if European League Against Rheumatism guidelines are followed, when a patient with RA does not reach remission or a state of low disease activity after 6 months of treatment, then the patient’s treatment should be modified regardless of the drug therapy being used (biologic or small molecule). However, according to their findings, most therapies were continued for 1 year or more before discontinuation. In total, say the authors, between 50% and 70% of the patients followed in this study remained on an RA treatment for an inappropriate length of time.
Reference
Tłustochowicz M, Śliwczyński AM, Brzozowska M, Teter Z, Marczak M. Sequentiality of treatment in the rheumatoid arthritis drug programme in the years 2009-2014. Arch Med Sci. 2018;14(3):569-571. doi: 10.5114/aoms.2016.58924.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.